Name Address/P.O. Box Postal Code/City Country Contact Person Telephone Email Website Social Media Number of Employees Founded (year) Areas of Activity
›
invIOs GmbH
›
Campus-Vienna-Biocenter 5 1030 Vienna Austria Peter Llewellyn-Davies +43-1-8656577 invios@invios.com www.invios.com
›
LI
› › › › › ›
›
35 2021
›
Immuno-Oncology
›
invIOs stands for innovative immuno-oncology (IO) and is focused on the discovery and development of cancer immunotherapies. invIOs is a fully owned subsidiary of APEIRON Biologics AG. We are pioneers in the research & development of cell therapies targeting novel immune checkpoints and in immunomodulation.
Our Innovative Immuno-Oncology Pipeline Despite successes with current therapies such as immune checkpoint inhibitors, there are large numbers of non-responders and patients who relapse following treatment. Due to these limitations, there is a huge demand for novel tumour therapies. The invIOs pipeline currently comprises two autologous cell therapy projects based on a platform technology targeting the master checkpoint inhibitor Cbl-b, as well as one small molecule asset. › APN401 is an out-patient cell therapy with a very short needle-to-needle treatment time. Based on our platform technology, Cbl-b is silenced in white blood cells, thus leading to a highly specific activation of innate and adaptive immune responses. It is our lead project, currently being evaluated in a clinical Phase Ib trial in patients with advanced solid tumours. › APN441 is a tumor-specific cell therapy approach utilizing our platform technology and Cbl-b to activate local, tumor-associated tumor infiltrating lymphocytes (TILs). It is in an early development stage for patients with glioblastoma. › INV501 is a novel small molecule candidate intended to activate anti-tumour immune responses and addresses a novel, undisclosed IO target.
